• June 3-6, 2024
  • San Diego Convention Center, California


Michael Atkin

Michael Atkin, MBA

Synergy Therapeutics Inc.
LIFE SCIENCES SUMMARY Translational research track-record from POC to development, with KOL support. Extensive financing/grants experience. Negotiated product partnerships, technology licenses and mergers. Strategic and operational skillsets. Serial start-up CEO, extensive board experience. PROFESSIONAL OBJECTIVES • To satisfy unmet medical needs by advancing early-stage technologies with POC, MOA and commercial value • To empower partnerships, financings and clinical studies with TPPs BIOTECH EXPERIENCE  CEO of oncology start-up Synergy Therapeutics based at PABC in Doylestown, PA. Philadelphia Coll. of Pharmacy/SJU spinout focused on fusion protein to restore p53 uptake for wildtype and mutant cancers  Sold antibiotic start-up founded by Larry Sutton, MD, PhD to syndicate of 3 US/Can. VCs; CEO of acquiror Gladius Pharmaceuticals Inc.  Founding CEO of Aegera Therapeutics, an apoptosis control company formed by merger of McGill and CHEO spinouts; raised $33m, advanced two FIC drugs to the clinic; generated $3m BD revenues  20 years of startup consulting and board roles in stem cells, regenerative medicine, SPR, oncology, novel drug drying and nanotherapy. NSF I-Corps mentor. CRO experience in biophysics. PHARMA EXPERIENCE  Senior product development, strategic marketing and licensing roles at BMS in neuroscience and Lederle Int’l (Pfizer) with oncology, ID & derm. partnerships
Speaking In


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.